N2OFF, Inc. (NITO)
NASDAQ: NITO · Real-Time Price · USD
1.695
+0.015 (0.89%)
At close: Jan 9, 2026, 4:00 PM EST
1.719
+0.024 (1.40%)
After-hours: Jan 9, 2026, 7:53 PM EST
N2OFF Revenue
N2OFF had revenue of $17.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $232.62K, up 39.81% year-over-year. In the year 2024, N2OFF had annual revenue of $210.00K, down -20.15%.
Revenue (ttm)
$232.62K
Revenue Growth
+39.81%
P/S Ratio
4.68
Revenue / Employee
$41,800
Employees
5
Market Cap
4.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 210.00K | -53.00K | -20.15% |
| Dec 31, 2023 | 263.00K | -131.00K | -33.25% |
| Dec 31, 2022 | 394.00K | -44.14K | -10.07% |
| Dec 31, 2021 | 438.14K | 205.87K | 88.63% |
| Dec 31, 2020 | 232.27K | 56.45K | 32.11% |
| Dec 31, 2019 | 175.82K | -250.77K | -58.78% |
| Dec 31, 2018 | 426.59K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rio Tinto Group | 53.73B |
| BHP Group | 51.26B |
| CRH plc | 36.90B |
| Linde | 33.50B |
| Freeport-McMoRan | 26.00B |
| The Sherwin-Williams Company | 23.28B |
| Newmont | 21.50B |
| Ecolab | 15.89B |
NITO News
- 6 days ago - N2OFF Advances $340,000 Payment to Gain Better Terms in Flag Solar Energy Initiative, Reflecting Approximately an Additional $1.7 Million in Project Profit Stake - GlobeNewsWire
- 13 days ago - N2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and Italy - GlobeNewsWire
- 7 weeks ago - N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination - GlobeNewsWire
- 2 months ago - N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers - GlobeNewsWire
- 2 months ago - N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer - GlobeNewsWire
- 3 months ago - N2OFF Stockholders Approve Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer - GlobeNewsWire
- 4 months ago - N2OFF Provides Business Update on Successful Execution of Solar and Energy Storage Initiatives Across Europe - GlobeNewsWire
- 4 months ago - N2OFF to Expand its Melz Solar Project with Battery Storage - GlobeNewsWire